Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Planned sale Sinha Vikas sold 2,707 shares at an average $1.56 ($4,220)
  2. 4 Planned sale Chief Executive Officer sold 1,325 shares at $1.98 ($2,619)
  3. 4 Planned sale Sinha Vikas sold 755 shares at $1.98 ($1,492)
  4. 4 Planned sale Chief Accounting Officer sold 222 shares at $1.98 ($439)
  5. 4 Planned sale Sinha Vikas sold 10,516 shares at $2.50 ($26,243)
  6. 4 Planned sale Chief Executive Officer sold 15,416 shares at an average $2.57 ($39,664)
  7. 4 Planned sale Chief Accounting Officer sold 1,653 shares at $2.50 ($4,125)
  8. 4 Planned sale Chief Executive Officer sold 8,342 shares at $3.56 ($29,710)
  9. 4 Planned sale Chief Accounting Officer sold 684 shares at an average $3.45 ($2,363)
  10. 4 Planned sale Sinha Vikas sold 2,635 shares at an average $3.44 ($9,077)
  11. 4 Planned sale Chief Executive Officer sold 5,275 shares at $3.05 ($16,063)
  12. 4 Planned sale Sinha Vikas sold 2,983 shares at $3.05 ($9,084)
  13. 4 Grant or award Chief Commercial Officer acquired 147,000 shares (grant or award)
  14. 4 Open-market buy 10% owner bought 2,930,870 shares at $3.75 ($10,990,763)
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market sale Chief Accounting Officer sold 5,045 shares at $5.64 ($28,453)
  17. 4 Planned sale Chief Executive Officer sold 4,536 shares at $4.21 ($19,115)
  18. 4 Grant or award Director acquired 35,000 shares (grant or award)
  19. 4 Grant or award Director acquired 35,000 shares (grant or award)
  20. 4 Grant or award Director acquired 35,000 shares (grant or award)

Page 8 of 19 · 363 filings